DBD — Insider Trading Activity
One insider at DBD put personal money into the stock on the open market this window, led by the CFO, with nobody selling.
What this means for DBD
DBD is not showing a cluster buy or a step-change versus its own baseline, so what the window amounts to is a single insider acting alone. Who is buying. The most credible buyer in this window is the company’s CFO (< $100K). That insider’s track record: past buys beat the S&P 500 2 of 2 times (avg +13% vs S&P over 6 mo). Overall credibility score: 23/100 (Low).
By the numbers. One insider filed 1 open-market purchase at DBD over the window, 700 shares in all at an average of $72.29 a share, most recently on July 31, 2026. No insider sold DBD stock on the open market in that period.
How we read these filings — which transaction codes count, how the cluster and credibility thresholds are set, and what the signals have and haven’t predicted — is written up in the insider trading methodology.
DBD insider filings, one by one
The single Form 4 filing from the last 90 days, with share count, dollar amount and date.
Other tickers with the same signal
Companies of a comparable size whose Form 4 filings tripped the same insider buying flag as DBD in this window.
- ATO insider trading — 1 buyer, credibility 15/100
- CSWC insider trading — 1 buyer, credibility 13/100
- ADTN insider trading — 1 buyer, credibility 25/100
- HWBK insider trading — 1 buyer, credibility 16/100
- DCX insider trading — 1 buyer, credibility 26/100